Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Firefly Aerospace Q1 2026 Earnings Call - Record $81M Revenue and Lunar Acceleration
Firefly Aerospace reported a record first quarter 2026, delivering $80.9 million in revenue and expanding its backlog to $1.3 billion, driven by a ramp in defense software and a successful Alpha rocke...
- Record quarterly revenue of $80.9 million surpassed all prior quarters, driven by a full quarter of SciTec defense software and a ramp in the FORGE missile defense program.
- Total backlog stands at approximately $1.3 billion, remaining flat sequentially as the company burned through backlog to generate record revenue.
- Management reiterated its full-year 2026 revenue guidance of $420 million to $450 million, citing strong demand across its spacecraft and launch portfolios.
- +9 more takeaways
Fabrinet Q3 FY2026 Earnings Call - Record Revenue and Earnings Beat Amid Supply Constraints and New Datacom Wins
Fabrinet delivered a record $1.214 billion in revenue for Q3 FY2026, accelerating 39% year-over-year and beating guidance on both top and bottom lines. Non-GAAP EPS hit a record $3.72, driven by stron...
- Revenue hit a record $1.214 billion, up 39% year-over-year and 7% sequentially, exceeding guidance.
- Non-GAAP EPS reached a record $3.72, beating guidance and reflecting strong operating leverage with expenses at 1.4% of revenue.
- Optical Communications revenue grew 35% year-over-year to $889 million, with Telecom surging 55% to a record $628 million.
- +9 more takeaways
Duolingo Q1 2026 Earnings Call - AI Content Velocity and the Monetization Paradox
Duolingo delivered a quarter defined by execution, not just ambition. Daily active users jumped 21% year-over-year as the company doubled down on teaching quality and product stickiness. The real stor...
- DAUs grew 21% year-over-year, meeting management's expectations for the strategic shift toward teaching quality.
- AI-driven content velocity hit a new peak with 20,500 course units published in Q1, a tenfold increase from two years ago.
- Professional proficiency content is now live across the top nine languages, reaching B2 level on the CEFR scale.
- +7 more takeaways
Vertex Pharmaceuticals Q1 2026 Earnings Call - Povi IgAN Data Sparks Renal Franchise Ambitions
Vertex Pharmaceuticals delivered a strong Q1 2026, with revenue rising 8% to $2.99 billion, driven by steady CF growth and early contributions from CASGEVY and JOURNAVX. The company's strategic pivot ...
- Q1 2026 total revenue reached $2.99 billion, an 8% year-over-year increase, with CF revenue growing 6% and new disease areas (CASGEVY and JOURNAVX) contributing approximately 25% of total growth.
- Povi (povetacicept) demonstrated 'sparkling' interim Phase III data in IgAN, achieving a 52% reduction in proteinuria and a 77.4% reduction in serum Gd-IgA1 levels, with a favorable safety profile showing no opportunistic infections.
- Vertex submitted the Biologics License Application (BLA) for Povi in IgAN just 27 days after database lock, marking the fastest regulatory submission in the company's history.
- +7 more takeaways
Allison Transmission Q1 2026 Earnings Call - Synergy Realization Begins as Defense and Mining Drive Growth
Allison Transmission reported a solid first quarter despite macroeconomic headwinds, with Adjusted EBITDA rising 22% year-over-year and adjusted EPS up 6%. The company’s acquisition of Dana Off-Highwa...
- Adjusted EBITDA rose 22% year-over-year to $362 million, with margins holding at 26% despite acquisition-related costs.
- Adjusted diluted EPS increased 6% to $2.57, excluding non-recurring acquisition expenses.
- Defense revenue jumped 64% year-over-year, driven by strong international demand for new transmission programs.
- +7 more takeaways
Advanced Energy Q1 2026 Earnings Call - Margin Breaks 40% as Data Center and Semiconductor Demand Accelerates
Advanced Energy delivered a standout first quarter, with revenue jumping 26% year-over-year to $511 million and gross margin cracking the 40% threshold for the first time since the Artesyn acquisition...
- Revenue surged 26% year-over-year to $511 million, beating the midpoint of guidance, driven by record data center revenue.
- Gross margin exceeded 40% for the first time since the Artesyn acquisition, reflecting improved product mix, manufacturing efficiency, and lower cost of sales.
- Data center computing revenue hit a record $194 million, up 102% year-over-year, with management raising full-year growth expectations to the mid-30% range.
- +7 more takeaways
REPAY Holdings Inc Q1 2026 Earnings Call - KUBRA Acquisition Doubles Scale and Drives Margin Expansion
REPAY Holdings delivered a solid Q1 2026, posting $80.8 million in revenue and a 4% year-over-year increase, while maintaining an impressive 43% Adjusted EBITDA margin. Management raised its full-year...
- REPAY reported Q1 2026 revenue of $80.8 million, up 4% year-over-year, with Consumer Payments growing 4% and Business Payments surging 18% year-over-year.
- Management raised its full-year 2026 Adjusted EBITDA margin outlook to approximately 42%, citing immediate accretion from a strategic distribution partner investment and volume routing optimizations.
- The company is aggressively pursuing the acquisition of KUBRA, which it believes will double its revenue, process over $130 billion in annual payment volumes, and create a comprehensive end-to-end digital platform.
- +7 more takeaways
V2X Q1 2026 Earnings Call - Record Backlog and Raised Guidance Signal Sustained Defense Demand
V2X delivered a record-breaking first quarter in 2026, with revenue surging 23% year-over-year to $1.25 billion and adjusted diluted EPS jumping 55% to $1.53. The company secured approximately $4.1 bi...
- Revenue surged 23% year-over-year to $1.25 billion, marking a record organic growth rate for V2X.
- Adjusted diluted EPS jumped 55% year-over-year to $1.53, outpacing revenue growth due to margin expansion.
- New contract awards totaled approximately $4.1 billion, including a major T-6 training program win, driving a 3.2x book-to-bill ratio.
- +7 more takeaways
Cryoport {Q1} 2026 Earnings Call - Raising Full-Year Guidance on Double-Digit Growth
Cryoport delivered a forceful start to 2026, reporting 16% year-over-year revenue growth to $47.8 million and raising its full-year guidance. The company’s integrated platform is working. Life Science...
- Full-year 2026 revenue guidance raised to $192 million - $196 million, reflecting strong early-year momentum and increased visibility.
- First-quarter revenue reached $47.8 million, a 16% year-over-year increase, driven by robust performance across both reporting segments.
- Life Sciences Services revenue grew 18% year-over-year, with BioStorage Bioservices leading the charge at 21% growth.
- +7 more takeaways
BioMarin Pharmaceutical Inc Q1 2026 Earnings Call - Amicus Acquisition Closes, 2026 Revenue Guidance Raised to $3.825B
BioMarin has officially closed its acquisition of Amicus, injecting high-growth enzyme therapies like Galafold and Pombiliti/Opfolda into its portfolio and immediately driving a 20% growth trajectory ...
- Amicus Acquisition Closed: BioMarin successfully closed its acquisition of Amicus last week, adding Galafold (Fabry disease) and Pombiliti/Opfolda (Pompe disease) to its commercial portfolio.
- Raised 2026 Revenue Guidance: Full-year 2026 revenue guidance is raised to $3.825 billion-$3.925 billion, reflecting a 20% year-over-year growth midpoint.
- Enzyme Therapies Growth: Enzyme therapies revenue guidance is raised to $2.725 billion-$2.775 billion, driven by a 30% growth midpoint after integrating Amicus assets.
- +9 more takeaways